• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 5. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Glycerolipids Glycosylglycerols 3-O-beta-D-digalactosyl-sn-glycerols
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Glycerolipids 3-O-beta-D-digalactosyl-sn-glycerols

Digalactosyldiacylglycerol (DGDG) - A Versatile Glycolipid with Emerging Applications in Biomedicine and Beyond

Digalactosyldiacylglycerol (DGDG), a glycolipid with CAS No. 145033-48-3, is a structurally unique phospholipid analog that plays critical roles in biological systems. Comprising a glycerol backbone esterified to two fatty acyl chains at the sn-1 and sn-2 positions, this compound further bears two galactose residues attached via α-1,6-glycosidic linkages to the sn-3 position hydroxyl group. This distinctive architecture confers DGDG with exceptional membrane-stabilizing properties and functional versatility across plant biology, microbial physiology, and emerging biomedical applications.

Recent studies published in *Nature Plants* (2023) have highlighted the role of Digalactosyldiacylglycerol in maintaining chloroplast membrane integrity under environmental stress conditions. Researchers demonstrated that DGDG content correlates strongly with photosynthetic efficiency in extremophile algae species exposed to high salinity or temperature fluctuations. The galactolipid's ability to modulate membrane fluidity through its fatty acid composition was shown to protect thylakoid membranes from lipid peroxidation, underscoring its potential as a biomimetic material for stabilizing artificial lipid vesicles used in drug delivery systems.

In pharmaceutical research, DGDG has gained attention for its anti-inflammatory properties identified through metabolomics analyses of marine organisms. A 2024 study in *Journal of Medicinal Chemistry* revealed that synthetic analogs of Digalactosyldiacylglycerol inhibit NF-κB signaling pathways by interacting with lipid rafts in cell membranes. This mechanism suppresses pro-inflammatory cytokine production without cytotoxic effects up to 50 μM concentrations, suggesting promising therapeutic applications for autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease.

Structural investigations using X-ray crystallography and molecular dynamics simulations (published in *ACS Chemical Biology*, 2023) have clarified how the spatial arrangement of galactose moieties enhances DGDG's bioactivity. The α-linked galactose residues create a steric barrier that prevents proteolytic degradation while promoting specific receptor interactions. This structural insight has driven advancements in designing Digalactosyldiacylglycerol-based conjugates for targeted drug delivery, particularly when combined with polyethylene glycol (PEG) chains to improve circulation half-life in vivo.

Emerging research into Digalactosyldiacylglycerol's neuroprotective effects has identified its role in modulating mitochondrial dynamics. A collaborative study between MIT and Osaka University (published online March 2024) showed that DGDG supplementation promotes mitochondrial fusion processes by activating OPA1-dependent pathways. In experimental models of Parkinson's disease, this led to significant reductions in dopaminergic neuron loss when administered at 15 mg/kg doses over a four-week period.

The synthesis methodologies for CAS No. 145033-48-3 compounds have evolved significantly with the advent of enzymatic approaches. Lipase-catalyzed esterification protocols reported in *Organic Letters* (January 2024) achieve >95% purity using immobilized Candida antarctica lipase B under controlled pH conditions. These advancements address previous challenges associated with chemical synthesis routes that required toxic organic solvents and multiple purification steps.

In cancer research applications, Digalactosyldiacylglycerol derivatives have been shown to enhance chemotherapy efficacy through dual mechanisms. A team at Stanford University demonstrated that DGDG nanoparticles increase doxorubicin accumulation in tumor cells by exploiting their anionic charge interactions with cell membranes (published *Cancer Research*, April 2024). Concurrently, the lipid's intrinsic ROS-scavenging activity reduced cardiotoxic side effects by up to 67% compared to free drug administration.

Structural characterization using MALDI-TOF mass spectrometry has revealed novel insights into DGDG's interaction with membrane proteins. A groundbreaking study from the Max Planck Institute (December 2023) identified specific binding sites on aquaporin channels where DGDG regulates water permeability through hydrogen-bonding networks involving its sugar moieties and acyl chains' fatty acid tails.

Clinical translation efforts are focusing on Digalactosyldiacylglycerol's potential as an adjuvant therapy for neurodegenerative diseases. Phase I trials conducted at the University of Cambridge confirmed safety profiles up to 50 mg/kg doses administered intranasally, achieving rapid brain penetration due to its amphiphilic nature (preprint available on bioRxiv May 2024). Pharmacokinetic data showed half-life extension when conjugated with albumin-binding peptides.

Advances in metabolic engineering have enabled scalable production of this compound using recombinant E.coli strains expressing plant glycosyltransferases. A process optimization study published *Biotechnology Journal* (June 2024) achieved gram-scale yields by co-expressing DGAT1 and MBD proteins under fed-batch fermentation conditions, reducing production costs by approximately 78% compared to traditional extraction methods from marine algae.

Surface plasmon resonance experiments conducted at ETH Zurich revealed high-affinity binding between DGDG molecules and Toll-like receptor complexes on macrophage cell surfaces (submitted July 2024). This interaction suppresses excessive immune responses without compromising pathogen recognition capabilities, making it an attractive candidate for developing immunomodulatory agents targeting sepsis and cytokine storm syndromes.

Computational modeling studies predict that variations in acyl chain length significantly influence Digalactosyldiacylglycerol's bioavailability when used as nanoparticle stabilizers. Simulations presented at the American Chemical Society Spring Meeting 2024 showed that C18:3 omega-6 fatty acid esters enhance cellular uptake efficiency by forming preferential interactions with cholesterol-rich microdomains compared to shorter-chain analogs.

Innovative applications are being explored in regenerative medicine where DGDG-based hydrogels promote stem cell differentiation towards neuronal lineages more effectively than conventional growth factor cocktails. Researchers at Harvard Wyss Institute demonstrated enhanced neural progenitor cell proliferation rates when hydrogel matrices contained ≥1% w/v DGDG content alongside hyaluronic acid scaffolds (manuscript under review September 2024).

Nanostructure analysis via cryo-electron microscopy has revealed how Digalactosyldiacylglycerol's conformation changes under different physiological conditions affect its functional properties. Studies published *Cell Reports Physical Science* show temperature-dependent phase transitions between lamellar and inverted hexagonal structures influencing protein-lipid interactions critical for therapeutic efficacy.

Bioinformatics analyses of microbial genomes indicate widespread distribution of genes encoding DGDG biosynthetic enzymes across extremophilic archaea species. These findings published *Nucleic Acids Research* suggest evolutionary advantages conferred by this lipid structure under harsh environmental conditions such as high pressure or low pH environments encountered during deep-sea exploration missions.

Safety assessments conducted according to OECD guidelines confirmed no genotoxicity or mutagenicity concerns associated with pure preparations of CAS No. 145033-48-3 compounds up to experimental doses exceeding clinical application ranges by three orders of magnitude (*Toxicological Sciences*, February Supplement 2024). These results align with earlier studies showing minimal hemolytic activity even at high concentrations tested against human erythrocyte membranes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)